Trial NCT05204589
Publication Li X, SSRN, 2023
Primary outcome on the report: Incidence of adverse reactions within 28 days after the boost immunization. The primary endpoint for immunogenicity was the serum geometric mean titer (GMT) of SARS- CoV-2 neutralizing antibodies against omicron BA.4/5 at 28 days after the booster dose, using a pseudovirus neutralization test (a vesicular stomatitis virus pseudovirus system expressing the omicron BA.4/5 spike glycoprotein), with a cutoff titer of 1:30

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.